Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol, quantity: 3.8 mg - drug delivery system, transdermal - excipient ingredients: isopropyl myristate; glyceryl laurate; ethyl oleate; acrylates/acrylamide copolymer - other conditions: do not remove from primary pack except for immediate use. indications: for short term treatment of the signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post menopausal bone mineral density loss. in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. for the prevention of post menopausal bone mineral density loss. when prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. lifestyle modifications and the risk benefit profile of climara should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.

Canada - English - Health Canada

biosyent pharma inc - tibolone - tablet - 2.5mg - tibolone 2.5mg - estrogens,antiestrogens,estrogen agonist-antagonists

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol valerate, quantity: 2 mg - tablet, sugar coated - excipient ingredients: magnesium stearate; macrogol 6000; sucrose; glycol montanate; calcium carbonate; povidone; maize starch; lactose monohydrate; purified talc - indications as at 19 july 2004: short term treatment of climacteric complaints after the cessation of monthly bleeding, or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness. progynova has also a favourable influence on bladder irritation (a not infrequent occurrence in the climacteric), signs of cutaneous and mucosal involution (particularly in the genital region) which normally occur with advancing age.

Canada - English - Health Canada

knight therapeutics inc. - estradiol (estradiol hemihydrate) - insert - 4mcg - estradiol (estradiol hemihydrate) 4mcg - estrogens

Canada - English - Health Canada

knight therapeutics inc. - estradiol (estradiol hemihydrate) - insert - 10mcg - estradiol (estradiol hemihydrate) 10mcg - estrogens

Canada - English - Health Canada

knight therapeutics inc. - estradiol (estradiol hemihydrate); progesterone - capsule - 0.5mg; 100mg - estradiol (estradiol hemihydrate) 0.5mg; progesterone 100mg - progestins

Canada - English - Health Canada

knight therapeutics inc. - estradiol (estradiol hemihydrate); progesterone - capsule - 1mg; 100mg - estradiol (estradiol hemihydrate) 1mg; progesterone 100mg - progestins

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 1.56 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 1.17 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - estradiol, quantity: 0.78 mg - drug delivery system, transdermal - excipient ingredients: dipropylene glycol; povidone; oleyl alcohol; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; colloidal anhydrous silica; butylated hydroxytoluene; 2,6-di-tert-butyl-4-ethylphenol; calcium stearoyl lactylate; epoxidised soy oil; erucamide; ethylene/vinyl acetate copolymer; magnesium hydroxide; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; polyethylene; silica; stearamide; synthetic paraffin; tetrasodium pyrophosphate; vinyl acetate; quartz; 1,1-dichloroethylene, chloroethylene polymer; diatomaceous earth; oxidised polyethylene - short term treatment of symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (see clinical trails and dosage and administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.